-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Dhnpbz/D2fAjOmN5r6hosMBPJ4KMew7kRA0AXoWyBCYbMXXIdqsUYnog83+IA+5x p3QkLkD0a5rP4uX0G5ZpWA== 0000950103-09-000360.txt : 20090223 0000950103-09-000360.hdr.sgml : 20090223 20090223130949 ACCESSION NUMBER: 0000950103-09-000360 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20090223 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20090223 DATE AS OF CHANGE: 20090223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 09627261 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: R924 8EP BUSINESS PHONE: 441256894000 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: R924 8EP FORMER COMPANY: FORMER CONFORMED NAME: Shire Ltd. DATE OF NAME CHANGE: 20080523 FORMER COMPANY: FORMER CONFORMED NAME: Shire plc DATE OF NAME CHANGE: 20051125 FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp12634_8k.htm FORM 8-K
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): February 23, 2009

Shire plc
(Exact name of registrant as specified in its charter)
 
Jersey, Channel Islands
 
(State or other jurisdiction of incorporation)
 
0-29630                                                  98-0601486
(Commission File Number)                (IRS Employer Identification No.)
 
Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
 (Address of principal executive offices)                              (Zip code)
 
Registrant's telephone number, including area code               44 1256 894 000
 
 
 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

 
 
 
 
Item 8.01.  Other Events
 
     Shire plc has issued the press releases attached hereto as Exhibit 99.01 and 99.02 which are incorporated by reference herein.
 
 
Item 9.01.  Financial Statements and Exhibits
 
                  (d)  Exhibits.  The following exhibits are filed herewith:
 
99.01            Press Release dated February 23, 2009
99.02            Press Release dated February 23, 2009

 
 
 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  SHIRE PLC
   
   
 
By:
   /s/ A C Russell
    Name: 
Angus Russell
    Title:
Chief Executive Officer
 
 
Dated: February 23, 2009
 
 
 
 
 
EXHIBIT INDEX
 
 
Number
Description
   
99.01
Press Release dated February 23, 2009
   
99.02
Press Release dated February 23, 2009
 
 
 
 
 
 EX-99.1 2 dp12634_ex9901.htm EXHIBIT 99.1
 
Exhibit 99.1
 
Press Release
www.shire.com
  
 
 
Director/PDMR Shareholding

February 23, 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on February 20, 2009 the following Persons Discharging Managerial Responsibility (“PDMRs”) were granted awards under the Shire Portfolio Share Plan (the “Plan”).

Awards of Stock Settled Appreciation Rights (“SARs”) under Part A of the Plan

Name of PDMR
Type of Security
No of Ordinary Shares or ADSs
Exercise price
Angus Russell (Executive Director)*
Ordinary Shares
295,580
£8.83
Graham Hetherington (Executive Director)*
Ordinary Shares
100,000
£8.83
Tatjana May
Ordinary Shares
  40,000
£8.83
Joseph Rus
Ordinary Shares
  30,000
£8.83
Michael Cola
ADSs
  20,000
$38.63
Sylvie Gregoire
ADSs
  20,000
$38.63
Barbara Deptula
ADSs
  12,000
$38.63
Anita Graham
ADSs
  12,000
$38.63
*Awards to Executive Directors are subject to performance targets

SARs will normally vest after three years, subject to any performance targets.  Once vested, SARs will be capable of exercise for a period of two years.  No consideration was paid for the grant of the SARs.

Performance Share Awards (“PSA Awards”) under Part B of the Plan

Name of PDMR
Type of Security
No of Ordinary Shares or ADSs
Market value
Angus Russell (Executive Director)*
Ordinary Shares
221,685
£8.83
Graham Hetherington (Executive Director)*
Ordinary Shares
  75,000
£8.83
Tatjana May
Ordinary Shares
  30,000
£8.83
Joseph Rus
Ordinary Shares
  20,000
£8.83
Michael Cola
ADSs
  15,000
$38.63
Sylvie Gregoire
ADSs
  15,000
$38.63
Barbara Deptula
ADSs
    9,000
$38.63
Anita Graham
ADSs
    9,000
$38.63
*Awards to Executive Directors are subject to performance targets

The PSA awards will normally vest after three years, subject to any performance targets.  Once vested, sufficient ordinary shares or ADSs will be transferred or allotted to the participant within 30 days.  No consideration was paid for the grant of the PSA awards.
 
This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
 
Tony Guthrie
Deputy Company Secretary
 
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
For further information please contact:

Investor Relations   
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 617 551 9715

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.


For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
 
 
 
 GRAPHIC 3 shire_logo.jpg GRAPHIC begin 644 shire_logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#T`KP,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/WYW&@`W&@`W&@`W&@"NJ16T>U`L"=A]T#/\JF*C36B]G&` M)*&B]V,#RKQ#\:?@SX*D?3_$/Q0^'_ARYM]P?3;[Q9HEA>6Q!(8268O3,A!! M&"@ZUW4,ES%14/.['G"I$Q..!6T>&\XPLEA(Y/BL*X M;1]C42^]Q27S8K4,(N6\**A_>2_`\OG_`&X/V6=,G>QB^(ZM':D!YM.\*>,[ MNQ3<3EFO+7P^\008)+;L8&`/'_AZ/Q%X"\5:%K_AWSFMOMNEWL9AM;H$%[2\B MW#>5;:=I]C;RW5YP>:;]NR M?AO*^#<,L57]EA,5A$I5*]9QH4Z3M=QI*7NJVW-;GF]K*R.6:EAI^SI7P\*; MTC'1Z]7;7Y;(\1T_]GWQ3:?:K:ST'Q%XJ\0:3+)%J'AGX5Z-<^)8M!NP3YEK MXH\;V%M<:)87Z-Q)9:?+JMPA;;*87:O5GF^'R[EY:U/)*--7C5Q[&+H.G]F"M:_>2T3\E=GE/B;P=XG\`7PL]?\&:_ M\/;B0M]BLM?T75-#E95^\(7U2WC:Z('+,A/K@"O1PF(P\*?_``DXJG&G#>5. M<)*/JH-V,^1X)\M*#PBAT::_,^LOV6OVO_%7P`U;2O"OB>0:W\(KFXCM;_1K MJUMUU#PO;W$@6;5_#USY8E=8=S23:?,TD4R*XB$4K*TWS?$'!^%Q5.I+!T_[ M,S"FFX.+:C)I:0J*]E?9323B[7NM#;#J6":C'_9:,=ULX7ZK_+J?:/[9OPZ\ M-^"/A-\5?B!\.K2T\,>&/'Y^"EVR:`T6G:-JFO6NOZ_<3>);2TLF2.":;0[_ M`$B*298T^T;@YW,&:;Y3@W&U\)F.78&4G1KY5]>BN>[G1ING37LFWK95(S:5 MWR[;-6MTZ>%IU'27L(>X]-%%W=W9>37J?EQ\`7N+;XY_!VW^TW-NB?$WP4#$ M;F>!0&\06&05,N,>QK]#SG#+!91F=.C%8*G2PM?HEO3D98=?4ZE*,/\`9E"< M=-NJ/ZJ3U/UK^>CT`H`BG_U$^W_GC+MQ_N-36Z]4'30_DDU+1/%=AJ.I>3HO MBRW']H7Q"#2]>A$8-U,01BW^0'VK^CZ//!'PH\*:AXM\;:]IWA7PSI*;I[R_E\M&D8$Q6E MI`@,M[?2D$1VT"22R'(53@XO!Y=7Q-6&#RZC+VDMHQ5DEU;>T8KK)M)=61:& M%CNJ=./5Z'YK_$;XC_$G]HSPAXEUN>[N/V;?V/-$MWD\0^,]=T_9XX^).EFZ MBMUM=%TH)(UM8WER\4,<<.8Y'N0CRW;,;9?T'`Y;@."\3A\/2@L;Q-2=J5"G M+DH8*=F[SGI>45=MO5)72@O>,)2\^G?SV/SN\:_'#1=# MTZZ^'/P(\/W7PB^%;2)::WJ:3*/BA\0+-61)[KQIXIC(N(;.6,/(FAV,L-FA MDVR"3&U/M\'DM3!3CBLQK*>8817I0M[+"X.6Z5"D_=YD]'5FG-[JV[Q2C@E[ M*A'ZM2I;OX)_]O2Z?X59']%GPKM?`&G_``]\)67PM&C1^`[+1-/@\.)H!MUT M]+$6T>S/V;@7ASF?S<3>LV_P#"$Q%*VUYY4BR(RY`9'W1R.K;Y+F%?AS&X?% MY9-X1X>2R5M/[KZ-'X"I^P7^U7:_+ M9?"LVH@R(S'XN\$P#C(W`#Q#P#UQ_M?[5?L]+C#AG!+_`&',/JD:7_3FNOB_ M[AG(L*Z/\"ER+_%'_,^W_CUX<\9>`/\`@G-X4\*>.-.?P]XK\+ZIX1T6[L7O MK.^:VM;#Q1=P:0IN]/N9X)!_8ZV(`CE;:,*<$$#Y'(:^!I<;XC$9-/V>%KQK M3A*,7#65).?NR46O?S<'%6T5O>TVTV/S`^`$9L?CK\&X8 M1]E,7Q.\$@*/]&(+>(;#``K]!SFA]1RC,\.O]CIT\+7]S;>G(SP\?J\J*_W? MVZ36IK)TL$G3IQ=/DW2]U1_KR1XKX;_P""I&@+>Q6'BOX.ZSH> MG>8JR7?AWQ/9:M<6T1/S2?V;?Z=IWGD+SM6X4GH,[J]FOX7U,#3=#"8^%'D6 MD*E*5)7[';V.4HT2O;W-G=6X'VO3=1LY@LNGZE;N=LD$RJPW*PW)(CO^?XW)\5D6*G ME>*P[P-2A]G96>THM:2C+HU^::-J<(48)4U[*/;;U371GP9:W:-;?PTBEHI&C8JIU\':2I(R!U]Z^TCX;9G14:4<5A:*LGO5A MNK_\^S'GHX5."ISIJ'HOU/6_B%^VA\.OA?\`#[X4^/-3\)>,SI'Q5TR_U70] M/T^'1EU#2X;!+)Y8]5BN-5BB25A?Q;?(DF'RMDC'/%/A*3P]X6O_%M_>>)QHECI4&F:?>Z=9W1>XM-5G,+(=2BE+R*D M:QQ2,SC`WZ9QP3C>%\-2C5E2A&56-&-.ES\_/.,I+1PC?X;66MVM-0I*G1;I M1A*@HIR=[)65O/S/$OBE_P`%*OACX(U:Z\/_``Y\(ZMX\%C+)!-K;:A%X6\- MM-&Q5O[,FFM+J\U*WR#B<6L$;;MT;2(P:;U\O\.<=&E&EC*L,G5KJERN=6*> MOO)2C&#\N9M=4GH1+V>$3ITJ;@H>?*OEHW^!]G?!;XKZ=\1_@WX>^*FI:;;> M`].U.PU6_P!0L;_5H9[/1(-(U*_T^YGN-5FAM8Q;;;%YS))'$$5\-TR?E,TR M261YG7R:A%IX>4(QY8-2FYQC))03D[^]:R;NS:C".'HQCR?5E%-M-VM9M;Z= MCY'^)?\`P4E^#O@:_N-!\!^&=?\`B%-:220R7]G-!X:\-/(IVDV6HZA%+3TXJZA).I5C?^:,6HQ?DYW75(QE*C M@E[.G!P4.B]U1^;U_`\LT7_@J7IEO=K9>(/@KJ.E:=O`:;0_&%I>W=M&3R_V M2_T>RCF8#/RBXCSZUZ%7PN>`C]7H9A'"1ATG1=)7]8SDU_X"QQ:P_N^Q=&/E M*W+\FD?H7\%_CK\+?C;HTU]\.];$L]@L9UCPWJ$)TOQ)H+2DB/\`M'2I6+)" MS#"W,#3V[DD)*Q!`^(S3AS'<-55@\7AOJD->247^ZGWY9+KWBTI+JC6C&E07 MLZ2]DH;QV:]5^NQ[@O6O--A*`/"/CG\=OA]^SIX'G\4^+KI8GE,EMX=\,V+Q M+K'B75`FY;+3X'/[N!25:XO''E6\;[FW.T<R'99C MZS%YO@^$*%3)^$']4JT_=Q6/T]I.2WA2DMDG?WH^[':%Y7F9TJ'L9)K]W&EK M"ELH+NU_5^O8^Y?'?P[\/>.OAWXD^&EU"FF:%K^@7&@QK80QP#2T:$+I]S8P M)M2)[&YBMIX4&U0;=!P&KY#+,54R;&83'8-^RJ82HJB5[_"R[+^`/&?B?P' M.K;I8-!U>ZTZUN"W)^U:>KFTNP>XF@DSWKHQ618#E^I8K"4E3I[*I!7A?M+X MH_)HB$/J3]E34J2AT3M^&Q]G>!O^"B_Q_P#!?DZ=XD@\)>-K&,*C)K&E'P[J MPC7KC4M`:"'SC5G]ZM^1^@?P._;\^$/Q)U&Q\*>)[&[^%'B>^EBM;&TUV[@G\-:C> M2E42VLO$D20I;7$LK82*_@M-Q=51W=@)OBLV\/\`,.'X36$BJ^$PJ;DZ<7"K M".]Y4G=M);N#E;=I(UHNEA[4[?5N39/;7L_\TC1_X*)?Z%^S!KHL_P#0]OBW MP9MV?+C?JZYI<`6P6?T?8?N5"C7_`/2":G[JD_9?N>64?+J?SZ:;<:CH&H6- MUX?FN](U6TNH'TN2P=[.^M[XR*+9K-XB'2Z\XIL*$,&<8Y;]Y^SSA#`PE"DE MAJ=-/F4M(\K6O,GI:V]^AS)/!->R_P!D<-K:6D5W+H/A;3-.DM-!DNHQ+]BN]1U+S7U&]B+[9FBCAC\Q7",ZMYDWY MKBO$".7XB5+),#"CA\.VE4JRDG-7MS1C"RC%_9NV[;I/0Z:>%]C%>RD\-R[* M*7N_-[ON?!W[17[/&N_LP>/D\(2:G'J>CZKIPUKPKX@M+;["VI:9]HEM9HKR MR$LJV>IVMQ&4FC21T(DBD0[90J_8\+9S1QN#^L9=3_LRIAIZ>QSPH?4O=HOV"@KQ>VGIT9]??\`!+[Q=>Z%X^^(OPX$LEOHNN^$ M6\4VVG,QCBM-:T"]M;"6>%"<0RW&FZJ1(5`WBPAW'Y%KY;C_`"J&#P>"J*@L M-/!5O9-?`^2I%R2?E&4-.W,_YF;4%]7E4I6]A&,>9+;5/_)_@?F=J?\`R$M3 M_P"PE?\`_I5-7WM#X*7^&/Y(Y^GS9]V?M/?\FN_L3_\`8H>)O_1/A^OD^'_^ M1_Q5_P!?J7YU!5/X.'_PO]#XAT+Q'K_A2U\1:/H%W<:(GBS1D\+ZK'9B2UN= M0TBXU;3-5?2D,7S^7=7VEV*21J#YJ!HB"LA$WUE;"T<#*AR16$_LR?M87LE2 MFH2ASZZ7C&GAW@HKV+C0Y>CNG]RV.7_:+ M\:^*?A/X%\&_L>:=KM@NG_#*VN;CX@7WAR>[M]-\3>(-=U:^\0Z9I1>YB@F_ MLW3-+U*QDEMI(PKWLS;PWV2,OOP[@\&\7BN)L!1E@I8UI8:-1)2H4X0C3G/1 MM<]2<9)23TIK2W-,+_580H4)*DJ.[CHKMN2731)ZKOZ"_LF?L9:S\?8M2\2Z MCKD_@+X>:%?-I1U"SM(I-9UO5DBBGNK'2([G_1[6VMHIX//O)EE`>98XXG99 M3"^(^):7![IX;!T52QJCS\LFZ4*4&VE*=M6Y-/EBK:*[:TYEAL,\)=0?U:G! MVNM'?LNB\V?67Q+_`."7F@:+X4U'4_@UXV\3#Q-I=E-=V>@>)?[+GL=;DMXF ME:PMK[3K&SDTR^GV%87=9XO,=5<(K&1/F\GX_J8;$4J5?"4L#AN9)U,/S1E3 MN[^+/@5X^T3QAX M5FGT;5_#M[MO-)=I+6'4[`2A-5\/ZM`I'FVES$DD+HPS'($D3;)$K+^@9AE& M$KX.KE=>"H8:&/%>A`QZ-XCT+3="#5+6*[$$H4X$\+2-%(.SHX[5_/6 M+RZ62XFOEE2E]5GE]25.4-M4VKKR>Z\F>A"$:$5"$?9QBDTO4YGXJ_%#PA\$ M?A]X@\>>*9ULM&\/6N^.SB9%N]4U&<^5INC:53Q6(HX#`P]GSO=Z1A%:RG+M&*NWWV6K1+C3PE-\ONPA\M7LEYL_.?]E[X= M>)_VF_B5J'[4?QJ@7_A'-!U.;3_A5X,E#0Z'8SZ=<&1)+:TE^5]%TB-;:QB>9/#]] M9_\`"+>(W159VCL)H[B?3K^XVC`1Y+$N[M[2$N M>E"_\RM&<5YI3MU,X8=X)/ZO)14>C]U_+I^1^9]Y8W7A^ZNM,NK6?1;VPN)[ M.]L;N%]-NK.[MI6AN;6Y@D`>&XBF1T=&`960@\C][^@1C'+XQ^KR6#A%*491 M=E9JZ::T::=T^IDXO"7BE]4<.FQ^D^K_`!^&WQ&\ M'^$FU&ZD=+NYT87=I?:%-=S2$M+!_\$V;?[#^T3>6N/)\CX;^+?D_U6S-UHK= M*]CCG#+!9)&FH>PIPQ-'3;I,FA#ZM-I+V?LH2_0^%-3_`.0EJ?\`V$K_`/\` M2J:OJZ'P4O\`#'\D8=/FS[L_:>_Y-=_8G_[%#Q-_Z)\/U\GP_P#\C_BK_K]2 M_.H*I_!P_P#A?Z'GW["/@[3-?_:<\`6.HP1PV>@1ZWXM6S=!%&;[0-.DFTLL MC##>3JSG+RZL[_`.'/[5'Q]^$GA.P\!>`/%UOX=\,:7->W%I8? M\(EX=NV$^HW4M[=RR7M]I4T\SO<3.#\EGB)RQ>$=*JE%-^ MVJ0TBE&*48S25DNBUW^T$(O!05*FO90I[+E2WU?0[O\`X;U_:Q_Z*';_`/A" M>$O_`)1UP_ZG<-_]"]_^#ZW_`,L->>IW_P#)8GR+J^H:C=ZMJFLW*FSU'6-1 MO=5U!X+(64(OM1N9;N[DBM;:)(K9'N)I&$<2*BAL*`!7T]*G3R2G3P^&_P!@ MIX:,813ERM1BDDKMW>B6KU?4P=\*VJ?[AQ=WTU?ET/Z,?V"MZ_LG_">!Q)&; M2'QC9K'(K1F.&T^('BNVMD`8J1&MM'$B]L(`.GS?AG%V"HY=Q#F.%I45@H0= M&7(M-9X>DW][;E\SLP]+V-"E32]DH\VFWVI=#X#_`."E?Q(U35/B5X,^#6C7 M#V&D>&=,L=?O((W,$,_B;Q/-/9V$LX!VLEEI4:^46'RG5+@_Q?-]IXO?D7_<7)OZO*%*A^ZC32;Z:RV^Y?FS]A M/ASX'T;X8^`?"/@/0((;'1_"?A_3='MHXU\L%K6VC6XNG'>:YNO.N)&/+23N MQY:OR[&5U4Q&)Q%U0C4J3F^EN9Z+R25DO)(Z:<(T*<:4/W<::2_KU.]K,L_- MG_@I9\/KW7/@IX?\8:1:F3_A7'BI;[442/)M]#U^U;2;J].,E(H=0&E;ST"2 M,YX0U]OX=8R&49I6PN%E]26+I>G4XYT_8T8NFO9JC*[ MZ:/3\['XH_#'QA=_"'XA>#?&FD6D*W7@[Q!8:W%8OBU2\BMY<7M@[JN85NK% M[B`N!\OG;NU?J^/RF-7!8K**DG@Z6)IRA=:&&)[WPMJ^HV>B^)-$N)5!DL[[2 M;N=)=T;DKY\`E@?`:.1@P+_@V8\,YGD-66#KX*I2IP;Y:D(R=*:Z.,XJVO9V MDNJ1UTE1H15*#5-0^RVDU\OZ1TGC;XP_"7X8Z1^%?#=E;1&7R)-7L MC?SD`E8;#2;262[O;AR,+'!#(Q+=.:PPF2YA7E'!X'+ZL7%VLH2A&%^LI-*, M5YMHJ7LL''EM'"PA]G1/Y+<_F<^,_C.P\>_%GXA^.-`L9-`TSQ1XJU36=/LY MU2RN;>RN)MML]TD9*I>311QS3*"0)+AQEL9F_>\JPD^'\MP6!C-8>I@*,(2: M_=+F2UM?[*;LO)(XVE@I3Y5]54)-I?!IT/J/P]X*U#PC_P`$^?B-XGEADTNW M\7?&#PG+I*R(UIOTS0+FVTLWD8/`ADU(ZE$K#J;5CTQO^?K8B&"XSP."H-8! MY3@ZRG;W.2=1.?+Z\O*_^WBHTOJ5*7+^[7M(VZ:+3\[GS=^S]_R7+X.?]E-\ M$_\`J0V5>UF__(HS/_L%K_\`IN1-'^+1_P`:_,_JJ/4_6OY\/1/QY_X*K?Z[ MX&_[GQ"_]#\(5^F>'7PYM_W`_P#,_\`D11_[":/_MY&'^+_`+/Z'*_% MSN/YEOVO_A[>_"W]HGXCZ=%;OIFG:[K4_C?0)8$:*&?2_%,LFI.8&)`9;?5' MU&T8#HUH1W%?N_!^-A4R3`2PC]A+"05"HMFITERZ_P"*'++S4C@5/ZG*:HKV M:;YETTEK^=T?H]_P3<^*W@B[^&C_``>U.?1M)\:>%=7U6\T?3M02SL[G6_#V MLW+:DLVF>=AKVXL]0N+V*>&,L\<E/"X*K"$9N- MX*G4@N6TK?"I147%O1OF6Z-L,X8.G[&E;#*FW9/W+)ZZ?.]S]'-8N/!G@K1K MS7-;?P[X8T3287N+S5-073M,L;.&-2S/)<7`1$X!P,Y8X"@E@*^!P]+$0Y,- M@54LW:,(YCG;0EU-1=PV<\T%M;+]I^SRQ/(!! M'MD=T(R"7_/<9@Z.7XK$X'"U/:4\)4E34DG!3Y7RN23;Y5=.VKNM?M&]*$:5 M.$*+_`(L>*;3XI?"&[TY/$D>CV>C:UX7U"\&C?V@F MF/,=-U/1M4D!@@O4AF,,D%R8480PNDJL76;[;@KBG"K35K&#P_L9)T+4U!6<;V]&GM]YVGPL^,7[6?A;0].\ M*?$G]EOQ)XFN](@@TY?%GACQ9X0T]M22V01)=:G8:CJGV8W;HJF2X@NTC=LM MY2;B!R8[)^%55G4R;/Z67X:[E["K1K24+ZM0E&'-;M%QNMKL5)?4XJ$*+C&G MI>,HK?NKV^:9]'Z-XP^,^K1*J_!K2/`-OMRL_C+XBZ9=R6X.#_R"?!FFZIY[ MG)^1KZV^]RP_C^?E@2EF<\13I_9H8:4%K_?K2IV]>27H:Q?)[L**IQ7 M\TTK?*-_S1Z/:^'KNZT/4]$\82Z+KEGK-K/8W>EVFC/IFBKIUW;M;WFG&WNK MZ\FNX94D<-)-*"?,^5$W8KCC/#X"5*65J>7PP;4H2Y[SC).ZE>,8J+\DOFRX MPY(\L;4U'1)*RL^F[/Q<^/7_``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`T9/'`U$^%M(NM1&FF_/A?[ M(+S[*C>1YWV:XV;L;O)?'0U^@^'>/P.14\SOBZ65I^PY/:S5.]O:\W+>U[75 M^]TQA*"I\U^5;7Y3P[]@/X*_%?X>_'2YU;Q9\,_&OA'0?^$!\362 M:GKV@7VEV+7MQ<:2]O:BXN(U5;B012%4SD[&QTKU.,&HQPLG&%.5-0C)7::6MCXQO/V:OVA;/4-0;3O@C M\3[>'[=>O`R>$=4*JDES*RLI6+[K*00>X;_OOZJEGN1X6$(X/-<+@XT8QT]M M#LK]28X=T+^PHSIK_"S[1_:`^#'QWA&E&5!TXO1)IPVW,S]@OX(?%?X??M M"Z/K?BOX8^./"'AZW\*>++5M4UWP]?:7IMO.;Z#A7B"MPI7?U.+IX&I95J,7R7MM.#VC4C=VZ26DNC M7-[",()4']6)K2TTV8O9^)O"E MG>:_HAV\QW5GJVB12/:,5^8+<):S+DAD4@U^OY;G^25*:_LK&TL)%+6E5:I3 MC?=.$VD_6+E%]SGCA_J7\"FZ:ALXZ+[UM^!PP\/?&'Q)-:Z/#HOQ6UZ9'46> MEW6G^,]5%N_"H8+:[BF2$]`&`7'K79[;+,C4O85<)DZAO*,J%+UNXM,?+.C: M-.,\-V5I+\#]$_V4/^"??B@^(M&\>_&C2E\+>&]#N(-4TGP!*\,FM:]?02"6 MS_X2*&%WCT?1XYE622S=VN+@H(I$BB9O.^)SOC+"9=0JX+AJI[.K43A+$1O& M%.+TE[)NSG-IV4DN6-[IMEX7#K#.+I+V,8:J&S\K]EY;L_:N*"*VC6*%5@B0 M85$&T*!P`%'08K\HA&%%_YT`&T>_YT M`&T>_P"=`!M'O^=`%-+>&WA"0H(XEW;8@!L7/H,5G0H4\'"%"A'V=.&RCH)1 MC02C27LTND=!([>"QMQ%:Q+!#&/DBC`1%W'G`4"LU2IX2BH48\D:=[+U%"$: M,>2FN50V+NT>_P"==!0N/`OT%+DC1@HTURI=`]G&E%1IKD2[:'__9 ` end EX-99.2 4 dp12634_ex9902.htm EXHIBIT 99.2
 
Exhibit 99.2
 
Press Release
www.shire.com
  
 

Director/PDMR Shareholding

February 23, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on February 20, 2009 it was notified by Mr David Mott, a Non-Executive Director of the Company, of an acquisition on the same day of 5,000 American Depositary Shares, representing 15,000 ordinary shares of £0.05 each.  The American Depositary Shares were acquired at a price of $38.6737 per American Depositary Share.

Following this transaction, Mr Mott holds 25,000 American Depository Shares in the Company.

This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)of the Disclosure and Transparency Rules.


Tony Guthrie
Deputy Company Secretary
 

 
For further information please contact:

Investor Relations    
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 617 551 9715

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.


For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----